CMC FDA Questions Resolved, PIIIb Rollout Begins, $4M Raised, Commercialization Team In Place; Signed CRO And Lined Up Commercial Manufacturer; Despite ~5% Value Range Reduction Due To Dilution, Investment Hypothesis Remains >10x Return; Exploring Non-Dilutive Grant Funds
Maxim Group analyst Jason McCarthy upgrades Brainstorm Cell (NASDAQ:BCLI) from Hold to Buy and announces $2 price target.
DEF 14A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
10-Q - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
8-K - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Filer)
- Company reached alignment with the U.S. FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its planned Phase 3b clinical trial for NurOwn® in ALS - SPA in place for Phase 3b NurOwn® trial in ALS - Enhanced leadership team with appointment of Hartoun Hartounian Ph.D. as EVP and Chief Operating Officer, and promotion of Dr. Bob Dagher to EVP and Chief Medical Officer - Conference call and webcast at 8.30am ET today NEW YORK, Aug. 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the Second Quarter ended June 30, 2023 and provided a
NEW YORK, Aug. 7, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2024, and provide a corporate update, at 8:30 a.m. Eastern Time on Wednesday, August 14, 2024. BrainStorm's Chief Executive Officer, Chaim Lebovits, will present a corporate update after which participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Haro Hartounian, Ph.D., Chief Operating Officer, Bob Dagher, M.D., Chief Medical Officer
ACF Equity Research FROM ACF EQUITY RESEARCH HEALTHCARE TEAM LONDON, July 24, 2024 /PRNewswire/ -- NASDAQ: BCLI READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE UPDATE NOTE: BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) develops NurOwn® stem cell therapy for Neurodegenerative diseases (NDDs) – BCLI's first target is ALS (MND/Lou Gehrig's). Since initiation – PIIIb rollout begins. CMC FDA questions resolved, commercialization team in place, raised US$ 4m (gross) enabling PIIIb rollout start, signed a CRO and lined up a commercial manufacturer,
4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK, June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Hartoun Hartounian Ph.D. as its new EVP and COO, effective as of June 18, 2024. Dr. Hartounian brings a distinguished track record with over 32 years of experience in the biopharmaceutical industry, with a focus on cell and gene therapy. His career highlights include founding and leading BioCentriq, a state-of-the-art cell and gene therapy CDMO facility, which was successfully acquired for $73 mil
Dr. Dagher has extensive biopharma industry expertise in the development and approval of treatments for challenging neurological and rare diseases NEW YORK, July 12, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Bob Dagher, MD, as Executive Vice President and Chief Development Officer effective July 17, 2023. Dr. Dagher will serve on BrainStorm's executive leadership team reporting to Stacy Lindborg, Ph.D., co-CEO of BrainStorm. He will be responsible for the portfolio strategy and advancement of clinical development plans towards regulatory approval, includin
NEW YORK, June 20, 2023 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the appointment of Nir Naor, CPA, CFA, MBA (IMD), LL.M, as Board Member, chairman of its Audit Committee and member of its Governance, Nomination and Compensation Committee (GNC), effective June 20. Mr. Naor is replacing Mr. Malcolm Taub, who will retire from the same roles after 14 years of service on the Company's board of directors. "We welcome the addition of Nir as a new independent board member, and we are confident that his impressive corporate experience in both the U.S. and Europe will add further
NEW YORK, Aug. 7, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2024, and provide a corporate update, at 8:30 a.m. Eastern Time on Wednesday, August 14, 2024. BrainStorm's Chief Executive Officer, Chaim Lebovits, will present a corporate update after which participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Haro Hartounian, Ph.D., Chief Operating Officer, Bob Dagher, M.D., Chief Medical Officer
A conference call and webcast will be held Monday, July 8, at 8:00 a.m. Eastern Time NEW YORK, July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on Monday, July 8, at 8:00 a.m. U.S. Eastern Time. BrainStorm's President and Chief Executive Officer, Chaim Lebovits, will present the update, together with recently appointed Chief Operating Officer and EVP, Hartoun Hartounian, PhD. Bob Dagher, MD, Chief Development Officer, will also be on the call for Q&A. The Q
Company received written agreement from the U.S. FDA under a Special Protocol Assessment (SPA) on the design for a Phase 3b trial of NurOwn® Conference call planned for later this quarter to provide update on NurOwn program NEW YORK, May 14, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the First Quarter ended March 31, 2024 and provided a corporate update. "We recently achieved an important milestone on our Debamestrocel (NurOwn®) development program, reaching agreement with the US FDA on a Special Protocol Assessment for our planned Phase 3b tri
4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
4/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Issuer)
Maxim Group upgraded Brainstorm Cell from Hold to Buy
Maxim Group upgraded Brainstorm Cell Therapeutics from Hold to Buy and set a new price target of $12.00
SC 13G/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)
SC 13G/A - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)
SC 13G - BRAINSTORM CELL THERAPEUTICS INC. (0001137883) (Subject)